about
Nutraceuticals in Parkinson's DiseaseLRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesPhosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPasesThe LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions.Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia.α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models.Decoding Parkinson's Disease Pathogenesis: The Role of Deregulated mRNA Translation.LRRK2 mutations and neurotoxicant susceptibilityAge-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein PathologyRab GTPases: The Key Players in the Molecular Pathway of Parkinson's Disease.Neuropathology of α-synuclein propagation and braak hypothesis.Synaptic signalling and its interface with neuropathologies: snapshots from the past, present and future.199 years of Parkinson disease - what have we learned and what is the path to the future?Sirtuins as modifiers of Parkinson's disease pathology.Biological functions of selenium and its potential influence on Parkinson's disease.Cutaneous malignant melanoma and Parkinson disease: Common pathways?Exploring the power of yeast to model aging and age-related neurodegenerative disorders.Rabs, Membrane Dynamics, and Parkinson's Disease.Selective neuronal vulnerability in Parkinson disease.Sec16 in conventional and unconventional exocytosis: Working at the interface of membrane traffic and secretory autophagy?Models of LRRK2-Associated Parkinson's Disease.From the baker to the bedside: yeast models of Parkinson's disease.Regulation of LRRK2 promoter activity and gene expression by Sp1.Animal models of α-synucleinopathy for Parkinson disease drug development.68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment.Novel animal model defines genetic contributions for neuron-to-neuron transfer of α-synuclein.LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity.Synapses in neurodegenerative diseases.Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.iPS cells in the study of PD molecular pathogenesis.The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease.Levetiracetam Affects Differentially Presynaptic Proteins in Rat Cerebral Cortex.Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.LRRK2: An Emerging New Molecule in the Enteric Neuronal System That Quantitatively Regulates Neuronal Peptides and IgA in the Gut.Current perspective of mitochondrial biology in Parkinson's disease.Mitochondrial Dysfunction in Parkinson's Disease.
P2860
Q26752769-33FBDC74-97B8-4531-8266-4F877B1B0179Q28078899-4D12DA56-4C06-4D91-AE3B-644A8B910351Q28119192-F6A63429-4139-4686-A55E-0CF1E226F1ECQ33905778-B559A5F9-6E1C-4811-B93F-FD724BF42B35Q36208453-26E5B83C-7575-4958-A93A-BAB3AAEDBC27Q36607556-7719F2BC-D9CF-4F98-A296-64EB0531DCFAQ37053959-628C3E68-A961-4BA6-AB23-26E786B81DE4Q37071013-F22D41AF-09BB-4FC5-B590-E0EC6A21C60EQ37701053-43FF5055-0228-420F-80FF-E07C45AE4C01Q37707932-CD1F883F-A59C-40C8-B8FC-80DE02FCC784Q37724701-347662A4-659E-4C4B-AA54-3BE00FA53F6EQ38580816-B9224FBF-BC3E-484B-A115-857F1A4A5B90Q38802640-5FF65546-7A38-4047-A4F8-FA410DDCA7D0Q38825770-AA83D3AF-417F-4AE2-9B55-6A77C9F7029EQ38893382-B0DC9F31-A3AA-440F-9BC6-380015891101Q38935901-0FFC0F89-50F1-4485-B6A2-EA382EB067C2Q38985873-0E7DABEF-B369-43A9-9170-02ED8389F671Q38996403-38C1F171-32DF-42BF-AA16-3C47BBE8B17DQ39031304-EE807D76-79BE-484D-ACFE-A1D38CE96782Q39095738-21745D8B-DED8-4B45-9A01-A218255F77E8Q39119334-3048F2DF-6AD4-485E-976E-63B779E2FD79Q39206443-ACFB8C9A-EAFC-4FB9-9C62-54F26C3175B8Q39208122-80CFF63C-8DCD-4329-B163-6CB6A54DBAF9Q39322027-2F2647B2-ADFE-4FD7-AA52-D14CB94B077BQ40106906-C68F9C7D-B50B-4FCC-A907-06D1DC3CB068Q41075418-D90DCD22-780E-42DB-B911-96D62B7F9297Q41311746-A1C6DBB5-D087-4030-A717-F882399B8C93Q41646475-15BEBE74-FFD9-4C1C-A4FD-EFAB72507F3CQ42342648-D5EC969A-82A9-43EA-98DD-44560F3FA7B9Q42372493-9C51A151-BB9C-4F41-99DD-8E70AFFCFB29Q46579323-904C8426-F24B-41F8-91A6-23448BDF8D7AQ47217972-327F12BB-1427-4EAE-8B15-9EAAD4BADF13Q47222228-02AC59FA-988F-4697-83C0-51A15C86484FQ48003270-2308C07B-B810-46EB-BF86-904C0DF18FF7Q48560989-2422AAF9-5FF6-4BE3-AB6C-3D95124513F4Q49545058-5C59EACD-310D-4F7B-BDC9-60E45D4F578AQ50055669-B0FD1CD5-14E4-4FE6-B7EE-AD200B91B7DAQ50907644-BFE5D409-137B-4F62-842F-EEE403E9D89DQ52351688-388E1FC0-FC25-4D8A-B48D-7CEF8B9CE686Q53453128-B8E775D7-7224-4670-B7CE-218C1D926E69
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
LRRK2 pathobiology in Parkinson's disease.
@en
type
label
LRRK2 pathobiology in Parkinson's disease.
@en
prefLabel
LRRK2 pathobiology in Parkinson's disease.
@en
P2860
P356
P1476
LRRK2 pathobiology in Parkinson's disease.
@en
P2093
Ian Martin
Jungwoo Wren Kim
P2860
P304
P356
10.1111/JNC.12949
P407
P577
2014-10-10T00:00:00Z